Off-label prescribing means a doctor uses a medication for a purpose, a dose, or a patient group that the drug’s regulatory approval doesn’t cover. It is legal, extremely common, and sometimes backed by strong evidence, though not always. Estimates of how frequently it happens range from roughly one in ten to one in four prescriptions, depending on how “off-label” is defined. Some of the most familiar examples include a blood-pressure pill taken before a concert to calm stage fright, a diabetes drug prescribed to restore ovulation, and an antipsychotic given at a fraction of its approved dose to help someone sleep.
How Common Is Off-Label Prescribing?
The short answer is that it depends on how strictly you define “approved indication.” A large cross-sectional study of U.S. prescriptions found that under a narrow reading of each drug’s labeling, only about 56% of prescriptions were clearly on-label. When the definition was broadened to capture closely related uses, roughly 75% were on-label, leaving about a quarter classified as off-label.1PubMed Central. Prevalence and relationship with health of off-label and contraindicated drug use in the United States: a cross-sectional study An earlier analysis of U.S. office-based prescribing estimated about 150 million off-label prescriptions in a single year, putting the rate at around 21% of all use for the drugs sampled.2JAMA Internal Medicine. Off-label Prescribing Among Office-Based Physicians A Canadian primary-care study found a somewhat lower rate of 11%, but noted that nearly four in five of those off-label prescriptions lacked strong scientific backing.3JAMA Internal Medicine. Drug, Patient, and Physician Characteristics Associated With Off-label Prescribing in Primary Care
Certain drug classes see far more off-label use than others. Heart medications, anticonvulsants, and asthma drugs have all been found with off-label rates above 40%.4JAMA Internal Medicine. Off-label Prescribing Among Office-Based Physicians Anticonvulsants are a particularly striking case: drugs originally approved for seizures have become workhorses for nerve pain, mood stabilization, and migraine prevention, so a huge share of their prescriptions fall outside the original approval.
Why Off-Label Use Is Legal
The FDA approves drugs, not medical decisions. Once a medication clears the approval process for any indication, physicians can legally prescribe it for other purposes based on their own clinical judgment. The FDA itself has acknowledged that it does not regulate the practice of medicine, which is why off-label prescribing has become so embedded in routine care.5PubMed Central. Ten common questions (and their answers) about off-label drug use This creates a gap between what a drug is marketed for and what it is actually used for in practice. Manufacturers are prohibited from promoting unapproved uses, but doctors are free to prescribe as they see fit. That tension is a recurring theme in off-label use.
Everyday Off-Label Prescriptions You May Recognize
Many of the most common off-label uses are so routine that patients never realize the prescription is technically unapproved for their condition. Here are some of the best-documented examples.
Gabapentin for Pain, Anxiety, and More
Gabapentin was approved as an anticonvulsant for seizures and later for a specific type of nerve pain following shingles. In practice, it is prescribed for a much wider menu of problems. Physicians use it for migraines, fibromyalgia, various psychiatric conditions, and as an alternative to opioids for chronic pain.6PubMed Central. Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern? It is also widely prescribed off-label in psychiatry.7PubMed. Outpatient Off-Label Gabapentin Use for Psychiatric Indications Among U.S. Adults, 2011-2016 The catch is that evidence reviews have found modest to no benefit for several of these off-label uses, which makes gabapentin a good illustration of how popularity can outstrip proof.8PubMed Central. Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?
Quetiapine for Insomnia
Quetiapine is an antipsychotic approved for schizophrenia, bipolar disorder, and as an add-on for major depression. At its approved doses, typically 150 to 800 mg per day, it is a serious psychiatric medication. But at much lower doses, often 25 to 200 mg, it is one of the most commonly prescribed off-label sleep aids.9PubMed. Safety of low doses of quetiapine when used for insomnia Its sedating side effects, which are a nuisance for patients taking it for psychosis, become the whole point of the prescription at bedtime. This is a pattern you see often in off-label use: a drug’s side effect profile becomes its therapeutic profile for a different condition.10PubMed. Effects of quetiapine on sleep: A systematic review and meta-analysis of clinical trials
Propranolol for Stage Fright
Propranolol is a beta-blocker approved for high blood pressure, certain heart rhythm problems, and migraine prevention. It has become one of the very few medications with a track record for managing performance anxiety, sometimes called stage fright. Musicians, public speakers, and others facing high-stakes performances take a low dose beforehand to blunt the physical symptoms of adrenaline: the racing heart, shaking hands, and trembling voice. In most countries, this use is considered off-label.11PubMed Central. Propranolol versus Other Selected Drugs in the Treatment of Various Types of Anxiety or Stress, with Particular Reference to Stage Fright and Post-Traumatic Stress Disorder The logic is straightforward: propranolol blocks the receptors that adrenaline acts on in the heart and muscles, so the fear response still happens in the brain but its most visible physical symptoms are dampened.
Spironolactone for Acne and Hair Loss in Women
Spironolactone is a diuretic originally designed for heart failure and conditions involving fluid retention. Because it also blocks androgen receptors, dermatologists prescribe it off-label to treat hormonal acne in women, female-pattern hair loss, and excess body hair. For acne, it carries level 1-2 evidence and can reduce the need for long courses of antibiotics.12PubMed. Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism This is one of those cases where the off-label use has become so standard within dermatology that many practitioners would be surprised to hear anyone question it, even though the drug has never been formally approved for skin conditions.
Metformin for Polycystic Ovary Syndrome
Metformin is approved for type 2 diabetes, but it has become a mainstay in treating polycystic ovary syndrome (PCOS), a hormonal condition that can cause irregular periods, excess androgen levels, and infertility. Studies have shown that metformin improves insulin sensitivity, lowers androgen levels, helps restore regular menstrual cycles, and can trigger ovulation in women with PCOS.13PubMed Central. Role of Metformin in Polycystic Ovary Syndrome (PCOS)-Related Infertility It is widely used to improve reproductive outcomes in this population.14PubMed. Effects of metformin treatment on pregnancy outcomes in patients with polycystic ovary syndrome In adolescents with PCOS, research has found that low-dose metformin combined with oral contraceptives produced improvements in insulin resistance, body weight, and androgen profiles that persisted even after treatment stopped.15PubMed Central. Sustained Metabolic Improvements with Low-Dose Metformin Combined with Oral Contraceptives in Female Adolescents with PCOS: A Single-Center Retrospective Cohort Study
Low-Dose Naltrexone for Chronic Pain and Inflammation
Naltrexone is approved at full doses (50 mg) for opioid and alcohol dependence. At much lower doses, typically 1 to 5 mg, it has been used off-label for chronic pain and inflammatory conditions including multiple sclerosis, fibromyalgia, and Crohn’s disease. Current evidence supports its safety and tolerability, and studies show subjective benefits over placebo, though evidence for more objective measures remains limited.16PubMed. The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn’s Disease, and Other Chronic Pain Disorders Low-dose naltrexone has become something of a grassroots phenomenon, with patient communities advocating for it well ahead of the formal clinical evidence. That enthusiasm is understandable given the lack of satisfying treatments for many chronic pain conditions, but it also makes this a space where expectations can run ahead of what the data actually show.
Off-Label Targeted Therapies in Cancer
Oncology is one of the most active frontiers for off-label prescribing, and the logic is different from the everyday examples above. Modern cancer treatment increasingly relies on genetic profiling of a patient’s tumor. When a tumor carries a specific mutation, a targeted drug designed for that mutation in one cancer type may work against the same mutation in a completely different cancer type. This creates a natural push toward off-label use: the mutation is the target, not the organ where the cancer happens to live.
A large precision oncology program that performed genetic profiling on over 18,000 patients found that about 1% received off-label targeted therapies based on their tumor’s molecular profile. Among those patients, thyroid and breast cancers had the highest rates of off-label targeted prescriptions. The most commonly targeted gene alterations included BRCA1, BRCA2, ERBB2, and BRAF. Roughly 27% of patients who stayed on treatment long enough to evaluate had a measurable response, and patients whose mutations had stronger published evidence for the off-label drug did better than those with weaker evidence.17PubMed Central. Molecular-Guided Off-Label Targeted Therapy in a Large-Scale Precision Oncology Program A separate analysis at another major cancer center found a similar pattern, with colon cancer, non-small-cell lung cancer, and cholangiocarcinoma among the most common cancer types receiving off-label targeted treatments, and BRAF mutations once again leading the list of molecular rationales.18PubMed Central. Real-World Analysis of Off-Label Use of Molecularly Targeted Therapy in a Large Academic Medical Center Cohort
The promise here is real but comes with challenges. Targeted therapies tend to be expensive, and the genetic profiling itself adds cost. Reimbursement for off-label use of these drugs can be difficult to secure, especially when the evidence base is still thin for a particular cancer-mutation combination.19PubMed Central. Off-label use of targeted therapies in oncology For patients who have exhausted standard treatment options, though, molecularly guided off-label therapy represents one of the more rational forms of off-label prescribing available.
The Safety Question
Off-label use is not inherently dangerous, but it is not inherently safe either. The distinction that matters most is whether the off-label use has good scientific support. A large study tracking adverse drug events found that off-label prescriptions had a higher rate of side effects compared to on-label use, at roughly 19.7 adverse events per 10,000 person-months versus 12.5 for on-label use. But when the researchers separated off-label prescriptions backed by strong evidence from those without it, the picture changed dramatically. Off-label use with strong scientific support had essentially the same side-effect rate as on-label use. It was the poorly supported off-label prescriptions that drove the excess risk.20JAMA Internal Medicine. Association of Off-label Drug Use and Adverse Drug Events in an Adult Population
That finding carries a practical message. When your doctor prescribes something off-label for a use backed by published guidelines or solid clinical trial data, the safety profile is similar to what you’d expect from an on-label drug. When the off-label use is more speculative, the risks are higher and less predictable. Asking your prescriber about the evidence behind an off-label prescription is reasonable and appropriate. In intensive care settings, a review of off-label medication uses found that published clinical guidelines existed for just over half of the off-label indications examined, and the vast majority of those guidelines supported the off-label use.21PubMed. Characterization of Guideline Evidence for Off-label Medication Use in the Intensive Care Unit That suggests off-label use in many clinical settings is not a shot in the dark but rather a well-trodden path through territory where formal FDA approval simply never followed the evidence.
Children, Newborns, and Rare Diseases
Pediatric medicine is one of the areas where off-label prescribing is most widespread and most necessary. An enormous number of drugs still carry no pediatric dosing or safety information on their labels, because the clinical trials that led to approval were conducted in adults.22PubMed. Off-label use of drugs in children At least a third of hospitalized children receive off-label prescriptions, and in neonatal intensive care units the figure may reach 90%. Implementation of regulations meant to encourage pediatric drug studies has been slow to change this picture.
Rare diseases make the situation even more acute. When a disease affects only a handful of patients per million, the commercial incentive to run large clinical trials and seek formal approval is often absent. That leaves patients and families relying on off-label options. For children with rare diseases, the majority of medications they receive have no or limited information in their labeling for pediatric use.23PubMed Central. Off-label medication use in rare pediatric diseases in the United States Clinicians in these settings often consult published case series, expert opinion, or analogy to related conditions when choosing a treatment. In a qualitative study of rare-disease stakeholders, most participants accepted off-label use when the drug was reasonably safe, when the labeled indication was general enough to suggest relevance, and especially when other options had failed.24PubMed Central. Off-label use of orphan medicinal products: a Belgian qualitative study
Manufacturer Promotion and the Regulatory Boundary
While doctors are free to prescribe off-label, drug manufacturers are not free to promote those uses. The FDA prohibits companies from marketing drugs for unapproved indications on the grounds that doing so would encourage widespread use before safety and efficacy have been properly established.25PLoS Medicine. Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints Despite this prohibition, off-label marketing has been a persistent problem. Multiple major pharmaceutical companies have settled federal investigations into alleged off-label promotion campaigns, paying billions in fines over the years.
The playbook typically involves funding research that highlights off-label uses, paying physicians to give talks about unapproved indications, or training sales representatives to steer conversations with doctors toward off-label applications. Whistleblower lawsuits have revealed these strategies in detail.26PLoS Medicine. Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints The tension is built into the system: a manufacturer profits from every prescription regardless of indication, so the financial incentive to expand use beyond the label is constant, even though the legal boundary says otherwise.
What Your Doctor Should Tell You
If you receive an off-label prescription, your doctor has a responsibility to inform you. Informed consent is a legal prerequisite for medical treatment, and it requires the physician to explain the benefits and risks that matter to the patient’s decision, not just the ones the physician considers important.27PubMed. Off-label and unlicensed prescribing in Europe: implications for patients’ informed consent and liability In practice, many patients are never told that a prescription is off-label. Physicians may not think of it as noteworthy when the off-label use is widely accepted in their field, or they may worry that the label “off-label” will alarm a patient unnecessarily.
If you want to evaluate an off-label prescription, a few questions are worth asking: How much clinical evidence supports this use? Is it endorsed by any professional guidelines? What are the known risks at this dose for this condition? And is there an on-label alternative that might work as well? None of these questions imply that you should refuse the prescription. Many off-label uses are better supported by evidence than some on-label ones. The point is to be informed, not fearful.
Off-Label Use in Veterinary Medicine
Off-label prescribing extends well beyond human patients. In veterinary practice, using human-approved drugs to treat animals is routine, particularly for cats and dogs. The reasons are practical: many conditions seen in small animals have no specifically approved veterinary drug, the available veterinary formulation may not come in the right dose or form, or the human version is simply cheaper and more accessible. A study tracking prescriptions at a veterinary practice found that oral antibiotics, especially amoxicillin-clavulanate, were the most common off-label human drugs used in both cats and dogs, consistent with findings from other countries.28PubMed Central. OFF LABEL USE OF HUMAN DRUGS IN VETERINARY SMALL PRACTICE IN REPUBLIC OF NORTH MACEDONIA
The public-health concern here is different from what you’d worry about in human off-label use. For people, the worry is side effects. For veterinary off-label antibiotics, the bigger concern is antimicrobial resistance. Every antibiotic prescribed to an animal, especially one originally designed for humans, is another opportunity for bacteria to develop resistance that could eventually affect human medicine. Clearer veterinary guidelines and better regulation of this practice are areas where experts see room for improvement.29PubMed Central. OFF LABEL USE OF HUMAN DRUGS IN VETERINARY SMALL PRACTICE IN REPUBLIC OF NORTH MACEDONIA